Relative contribution of baseline variables in a nomogram to predict survival in patients treated with nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer

被引：0
|
作者：
David, Goldstein [1 ]
Daniel, Von Hoff [2 ]
Chiorean, E. [3 ]
Michele, Reni [4 ]
Josep, Tabernero [5 ]
Ramesh, Ramanathan [6 ]
Julia, Wilkerson [7 ]
Marc, Botteman [7 ]
Abdalla, Aly [7 ]
Sandra, Margunato-Debay [8 ]
Brian, Lu [8 ]
Chrystal, Louis [8 ]
Markus, Renschler [8 ]
Desmond, McGovern [9 ]
Chee, Lee [10 ]
机构：
[1] Prince Wales Hosp, Sydney, NSW, Australia
[2] TGen & HonorHlth, Phoenix, AZ USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Osped San Raffaele, Milan, Italy
[5] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[6] Scottsdale Healthcare TGen, Scottsdale, AZ USA
[7] Pharmerit Int, Bethesda, MD USA
[8] Celgene Corp, Summit, NJ USA
[9] Celgene, Stockley Pk, England
[10] Univ Sydney, NHMRC Clin Trial Ctr, Camperdown, Tyne & Wear, Scotland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O - 017
引用
收藏
页数：3
相关论文
共 50 条
  • [41] FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study
    Servetto, Alberto
    Santaniello, Antonio
    Napolitano, Fabiana
    Foschini, Francesca
    Marciano, Roberta
    Cascetta, Priscilla
    Amato, Anna Rita
    Augurio, Maria Rosaria
    Maresca, Lucia
    De Placido, Pietro
    De Placido, Sabino
    Formisano, Luigi
    Bianco, Roberto
    FUTURE ONCOLOGY, 2022, 18 (21) : 2643 - 2654
  • [42] Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer
    Lim, Alexander
    Kim, Dae Won
    Kim, Kunhwa
    Kim, Richard D.
    Bottiglieri, Salvatore Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [43] EFFICACY AND SAFETY OF NAB-PACLITAXEL IN COMBINATION WITH GEMCITABINE FOR METASTATIC PANCREATIC CANCER
    You, Min Su
    Ryu, Ji Kon
    Kang, Jinwoo
    Choi, Jin Ho
    Choi, Young Hoon
    Huh, Gunn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    GASTROENTEROLOGY, 2018, 154 (06) : S285 - S285
  • [44] Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
    Kamata, Ken
    Imai, Hajime
    Matsumoto, Hisakazu
    Yamashita, Yukitaka
    Kato, Takao
    Nishi, Katsuhisa
    Omoto, Shunsuke
    Minaga, Kosuke
    Yamao, Kentaro
    Hyodo, Tomoko
    Im, Sung-Woon
    Hara, Akane
    Yoshikawa, Tomoe
    Ishikawa, Rei
    Okamoto, Ayana
    Yamazaki, Tomohiro
    Nakai, Atsushi
    Ueshima, Kazuomi
    Chiba, Yasutaka
    Takenaka, Mamoru
    Watanabe, Tomohiro
    Kitano, Masayuki
    Kudo, Masatoshi
    JGH OPEN, 2023, 7 (09): : 659 - 666
  • [45] Gemcitabine plus Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study
    Zaibet, Simon
    Hautefeuille, Vincent
    Auclin, Edouard
    Lievre, Astrid
    Tougeron, David
    Sarabi, Mathieu
    Gilabert, Marine
    Wasselin, Julie
    Edeline, Julien
    Artru, Pascal
    Bechade, Dominique
    Morin, Clemence
    Ducoulombier, Agnes
    Taieb, Julien
    Pernot, Simon
    BRITISH JOURNAL OF CANCER, 2022, 126 (10) : 1394 - 1400
  • [46] Impact of Statin Use on Survival in Patients With Unresectable Pancreatic cancer Receiving Gemcitabine Plus Nab-Paclitaxel
    Saito, Kei
    Nakai, Yousuke
    Sasaki, Takashi
    Takeda, Tsuyoshi
    Ueno, Makoto
    Tezuka, Shun
    Isayama, Hiroyuki
    Tomishima, Ko
    Kojima, Yasushi
    Yamamoto, Natsuyo
    Ito, Yukiko
    Oyama, Hiroki
    Toda, Nobuo
    Takagi, Kaoru
    Matsubara, Saburo
    Mohri, Dai
    Sato, Tatsuya
    Fujishiro, Mitsuhiro
    PANCREAS, 2025, 54 (02) : e107 - e113
  • [47] Gemcitabine and nab-paclitaxel combination therapy for the treatment of metastatic pancreatic cancer
    Sasaki, Takashi
    Kanata, Ryo
    Saito, Kei
    Yamada, Ikuhiro
    Matsuyama, Masato
    Ozaka, Masato
    Takano, Kouichi
    Sasahira, Naoki
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy
    Nishioka, Mariko
    Okano, Naohiro
    Wakabayashi, Masashi
    Ikeno, Takashi
    Hayashi, Masato
    Mizutani, Tomonori
    Nagashima, Fumio
    Furuse, Junji
    ANTICANCER RESEARCH, 2024, 44 (03) : 1233 - 1239
  • [49] A cost-utility analysis of gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer.
    Ko, Yoo-Joung
    Tam, Vincent Channing
    Mittmann, Nicole
    Pasteka, Mark
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [50] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Yasin
    Karhan, Ogur
    Aldemir, Mehmet Naci
    Urun, Muslih
    Ercek, Berrak Mermit
    Urakci, Zuhat
    Arvas, Hayati
    Tunc, Sezai
    Erdem, Mehmet
    Yerlikaya, Halis
    Ileri, Serdar
    Aydin, Ibrahim
    Bicer, Abdurrahman
    Komuroglu, Ahmet Ufuk
    Majidova, Nargiz
    Gokcek, Savas
    Demir, Hacer
    Yildiz, Sedat
    Akbas, Sinem
    Ozen, Esra
    Kahya, Burcu Ulas
    Sali, Muersel
    Anik, Hicran
    Aykut, Talat
    Araz, Murat
    Alkan, Ali
    Ozcelik, Melike
    Sakin, Abudllah
    Aykan, Musa Baris
    Mehtiyev, Mirmehdi
    Demir, Bilgin
    Baser, Mehmet Nuri
    Sonmez, Muge
    Gulturk, Ilkay
    Avci, Niluever
    Urvay, Semiha
    Arici, Mustafa Ozgur
    Kalender, Mehmet Emin
    Yildirim, Mustafa
    Solmaz, Ali Alper
    Gurbuz, Mustafa
    Ergun, Yakup
    SCIENTIFIC REPORTS, 2025, 15 (01):
12345